Painchek Ltd · ASX:PCK
Painchek — Q1 FY25 Earnings Presentation
32 slides from Painchek's earnings presentation, Oct 30, 2024
Slide 1: Quarterly Update October 2024
For personal use only O ctober 202 4 Quarterly P H I L I P D A F F A S , C EO & M D P A I N C H E K L TD | A S X : PC K 1 |
Slide 2: Our purpose is to give a voice to people who cannot verbalise pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 3: The PainChek Universal App: Quick and Easy Operation
THE P AINC HEK ® UNIVERS AL A PP : QUIC K A ND EAS Y OPE RA TIO N AI based micro-facial pain expression analysis: For personal use only A medical • 3 second scan of patient face device in • Recognises 9 micro-facial your pocket expressions indicative of pain Guided digital questionnaire checklist: •
Slide 4: PainChek well positioned to exploit large global market opportunities
P AI NC HEK WELL PO SI T IO NED T O EXP LO IT L ARGE G LOB AL MA RKET OP PO RTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET 6 MILLION BEDS 1 UP TO 10X AGED 400M PRE-VERBAL ~$1Bn ANNUALLY 4 CARE MARKET 2 CHILDREN & - 150M ANNUALLY TO $300M ANNUAL FIRST TIME PAR
Slide 5: PainChek's three pillars of focus
P AI NC HEK ’S TH RE E PI LL AR S OF FOC US For personal use only 1 2 3 US market entry and Continued Direct to parent commercialisation – acceleration in growth market entry of the regulatory submission of PainChek Adult Infant App pending with De Novo App in international clearance targeted market
Slide 6: PainChek's three pillars of focus with Q1 FY25 highlights
P AI NC HEK ’S TH RE E PI LL AR S OF FOC US w / Q1 F Y25 HI G HL IG HT S For personal use only US market entry and Continued Direct to parent market commercialisation acceleration in growth entry of the Infant App of PainChek • FDA validation study • Early access programme complete • 100k global lic
Slide 7: Global licences reach 100K milestone; $4.8M annual recurring revenue
G LOB AL L I CE NC ES R EAC H 10 0K M IL EST O NE $4 .8 M AN NU AL R EC C UR R I NG R EV ENU E¹ For personal use only WW CONTRACTED LICENCES LICENCES / ARR $M 120,000 $4.61 $4.81 $5.00 31% increase in ARR1 over the prior year $4.30 $4.50 100,000 $3.90 SAAS business model with 70-85% $3.67 $4.00 % gr
Slide 8: Growth in customer receipts aligned to implementations
G RO WT H I N C U ST OM E R R EC EI PT S ALIGN ED TO IMPLEME NTATIONS For personal use only CUSTOMER RECEIPTS (A$M) QUARTERLY (COLUMNS) AND ANNUAL (LINE) $1.0 $3.5 53% increase in customer payments $0.9 Sep24 v Sep23 quarter $3.0 $0.8 $2.5 $3m cash receipts from customers for the $0.7 year ended Sep
Slide 9: Consistent growth in utility
CONS ISTENT GROWTH IN UTILITY For personal use only 8,000,000 7,440,000 7,000,000 Over 7 million to date global pain assessments 6,000,000 5,990,000 conducted on the PainChek platform 5,000,000 5,000,000 116% increase in global pain assessments 4,120,000 over the previous year in Aged Care alone 4,0
Slide 10: PainChek's international expansion
PAINCHEK’S INT ER NA TIO NAL EXPA NSIO N For personal use only W W CON T RACT ED LI CEN CE S B Y R EGI ON 120,000 Strong commercial presence in 100,322 ANZ, UK, and Canada 100,000 95,003 90,023 85,368 77,037 Strong pipeline of beds in pilot programs and 80,000 39,275 30,380 36,163 contracts in negot
Slide 11: PainChek across Australia
P AINC HEK AC R OSS A USTRA LIA AGED CARE’S MOST POPULAR DIGITAL CLINICAL TOOL Aged Care PainChek commercial licences cover around 60,000 beds NOTABLE EXISTING AUSTRALIAN AGED CARE CLIENTS (COVERING 25,000+ BEDS) For personal use only and 750 aged care homes, around 30% of total AU RAC market and ne
Slide 12: UK growth continues acceleration in aged care market
UK GROWTH CONTINUES A CCEL ERATION IN 50 0,0 00 B ED A GED CARE MARKET For personal use only UK CUSTOMER CONTRACTED LICENCES 39,275 40,000 36,163 93% increase in UK contracted beds to more than 35,000 39,000 beds across 1,000 homes over prior year 30,380 30,000 21,829 25,073 19,391 A$2.1M ARR in UK
Slide 13: PainChek's growing UK footprint
PAINCHEK’S GROWING UK FO OTPRINT IN A 5 00, 000 B ED MAR KE T • PainChek commercial licences in UK aged care cover more than 39,000 beds and 1,000 care homes. For personal use only NOTABLE EXISTING UK AGED CARE CLIENTS COVERING 12,500 BEDS. UNITED KINGDOM AGED CARE INTEGRATION PARTNERS PROVIDING ACC
Slide 14: What makes a successful medical device?
W HA T M A KE S A SU C CE SSF UL M ED I CA L D EV I CE? For personal use only Delivers on an unmet global medical need Improves health & Produces clinical Cost/benefit outcomes gain 14
Slide 15: Delivers on an unmet global medical need
WH AT MAKES A SUCCESS FUL MEDICAL DEVICE? - D EL IV ER S AN UN ME T GL OB AL M EDI C AL NEE D For personal use only World’s first regulatory Creates personalised validated medical device pain profiles that deliver for pain assessment improved outcomes Provides healthcare professionals PainChek combi
Slide 16: Improves health and clinical outcomes
WH AT MAKES A SUCCESS FUL MEDICAL DEVICE? - I MP R OVES HEAL TH & CL IN IC AL OUTC OM ES For personal use only SCOTTISH CARE ORCHARD CARE HOMES2 ORCHARD CARE HOMES2 INSPECTORATE1 PAIN MANAGEMENT MEDICATION MANAGEMENT • 100% increase in • Reduction in falls by frequency of pain • 33% reduction of 75%
Slide 17: Produces a cost/benefit gain
W HA T M A KE S A SU C CE SSF UL M ED I CA L D EV I CE? – P RO DUC ES A C OS T /BEN EFI T GA IN • Sample of four registered care homes selected for analysis in BLMK ICB For personal use only • Data collected Feb-Jun 2024 (Feb-Apr as pre-intervention period / May-Jun as post-intervention period) • Si
Slide 18: PainChek delivers on the core attributes of a successful medical device
P AI NC HEK D ELI VER S ON TH E CO RE A T TR I BUT ES O F A SUCCESSF UL MEDICA L DEVICE For personal use only Delivers on an unmet global medical need Improves health & Produces clinical Cost/benefit outcomes gain 18
Slide 19: Positive results pave way for FDA De Novo submission
P OSITIVE RES ULTS P AVE WAY FO R FDA DE N OVO SU B M IS SI ON – M AR K ET LA UN CH 2025 For personal use only US FDA de Novo Results from the Potential FDA Validation Study study, which clearance for delivers positive recruited 105 PainChek’s adult results – FDA patients at five sites app also prov
Slide 20: Market partnerships and drivers for USA and Canada
MARKET PA RTNE RS HIPS A ND D R IV ER S F OR U S A & C ANA D A For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN EARLY 2025 NORTH AMERICAN LONG TERM CARE PointClickCare: PainChek integrated MARKET OPPORTUNITY with PointClickCare leading long term care provider in USA
Slide 21: Meet PainChek Infant
For personal use only Meet PainChek® Infant A PainChek Limited Product 21
Slide 22: Meet PainChek Infant
M EE T P AI NC HE K ® I N F AN T For personal use only • The newest addition to the PainChek family, PainChek Infant, is the world’s first AI-enabled app for instant pain assessment on infants aged 1-12 months. • Designed for in-home use by parents or other non-medical carers, PainChek infant provid
Slide 23: Meet PainChek Infant features
M EE T P AI NC HE K ® I N F AN T For personal use only • PainChek® Infant app is a fully inclusive App and provides a range of value adding features for parents and family members, including: • 3-second pain assessment analysis • Monitoring historical pain events • Documenting treatments, including
Slide 24: Early access registration now open
EAR LY AC CESS REG IST RA TI O N NO W O PEN • PainChek Infant product is now available for use to a selected group of parents in For personal use only Australia • Eligible parents who sign up to the Early Access Program through the PainChek Infant website will be able to get pre-release access to th
Slide 25: Building brand and product awareness
BUILDING BRAND AND PRODUCT AWARENESS For personal use only Watch video >> “One of the hardest things about the parenting game is seeing your baby upset (and “There have been so many times that I spun down Google spirals, tossed and turned into the trying to figure out why your baby is actually cryin
Slide 26: Parent and professional endorsements
PARENT AND PROFESSIONAL ENDORSEMENTS For personal use only “Pain is not uncommon in young children, even those who cannot tell you they are in pain. While in the past it was thought young children including infant did not experience pain, this has been proven not to be true. Simple procedures such a
Slide 27: Now approved for the Apple App Store
NOW APPROVED FOR THE APPLE APP STORE For personal use only • PainChek Infant has entered the final phase of direct to parental testing • The PainChek Infant App is now becoming available directly through the Apple App store, driving growth in registrations and broad market entry in 2025 27 |
Slide 28: Corporate summary
CORPO RA TE S UMMARY For personal use only Top shareholders % Financial information Peters Investments Proprietary Ltd 7.3% Share price (29th October 2024) A$0.034 Founders 4.6% Shares on issue 1,637.3m Board & key staff 4.0% Market capitalisation AUD $55.6M Cash (30 September 2024) A$1.7M* Debt Nil
Slide 29: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 30: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 31: PainChek's three pillars of focus with Q1 FY25 highlights
P AI NC HEK ’S TH RE E PI LL AR S OF FOC US w / Q1 F Y25 HI G HL IG HT S For personal use only US market entry and Continued Direct to parent market commercialisation acceleration in growth entry of the Infant App of PainChek • FDA validation study • Early access programme complete • 100k global lic
Slide 32: Quarterly Update Contact
For personal use only Q uar t er ly Up d at e O ct o be r 20 24 CO N TA C T Ph ilip Da f fa s, CEO & MD p hili p. da f fa s@ pa inc h ek .c o m P A I N C H E K L TD | A S X : PC32 K